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Abstract

CLINICAL
SCIENCE

Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort.
Methods. Patients in the Systemic Lupus International Collaborating Clinics inception cohort (415 months
of SLE diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and
end-stage renal disease (ESRD). Health-related quality of life was measured by the Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental and physical component summary scores.
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The frequency and outcome of LN

Results. There were 1827 patients, 89% females, mean (S.D.) age 35.1 (13.3) years. The mean (S.D.) SLE
duration at enrolment was 0.5 (0.3) years and follow-up 4.6 (3.4) years. LN occurred in 700 (38.3%)
patients: 566/700 (80.9%) at enrolment and 134/700 (19.1%) during follow-up. Patients with nephritis
were younger, more frequently men and of African, Asian and Hispanic race/ethnicity. The estimated
overall 10-year incidence of ESRD was 4.3% (95% CI: 2.8%, 5.8%), and with nephritis was 10.1%
(95% CI: 6.6%, 13.6%). Patients with nephritis had a higher risk of death (HR = 2.98, 95% CI: 1.48,
5.99; P = 0.002) and those with eGFR <30 ml/min at diagnosis had lower SF-36 physical component
summary scores (P < 0.01) and lower Physical function, Physical role and Bodily pain scores. Over
time, patients with abnormal eGFR and proteinuria had lower SF-36 mental component summary
(P 4 0.02) scores compared to patients with normal values.
Conclusion. LN occurred in 38.3% of SLE patients, frequently as the initial presentation, in a large multiethnic inception cohort. Despite current standard of care, nephritis was associated with ESRD and death,
and renal insufficiency was linked to lower health-related quality of life. Further advances are required for
the optimal treatment of LN.
Key words: systemic lupus erythematosus, lupus, nephritis, inception cohort, outcomes research.

Rheumatology key messages
.
.

Lupus nephritis is associated with a substantial risk of end-stage renal disease and death.
New treatment strategies are required to improve the outcome of lupus nephritis.

Introduction

Patients and methods

Renal disease affects 38% of patients with SLE, with a
range of 1269% [1]. The frequency and severity is
increased in patients with African, Hispanic and Asian ancestry [1]. Although a common early manifestation, it can
occur at any time in the disease course [2]. The presentation varies from subclinical laboratory abnormalities to
overt nephritis and nephrotic syndrome. Despite recent
advances, some studies report progression to end-stage
renal disease (ESRD) and mortality has not declined in the
last decade [3, 4].
Improved outcomes of nephritis result from better treatment of both primary pathogenetic mechanisms and secondary co-morbidities. Administration of i.v. CYC [5, 6]
and oral MMF are effective for induction [79] or maintenance therapy [10, 11]. Open-label studies of targeted Bcell depletion therapies have been positive [12, 13], although unconfirmed in controlled studies [14]. These
immunomodulatory strategies and treatment of comorbidities have been incorporated into recent treatment
guidelines [15, 16]. The value of future treatment strategies will be determined by comparison with current standard of care.
Between 1999 and 2012 the Systemic Lupus
International Collaborating Clinics (SLICC) established
the SLICC inception cohort for the long-term study of clinical outcomes in SLE. The objective of the current study
was to evaluate the short-term outcomes, as reflected by
health-related quality of life (HRQoL), ESRD and death in
patients with LN receiving standard of care in this international multi-ethnic/racial observational cohort of newly
diagnosed SLE patients.

Research study network

www.rheumatology.oxfordjournals.org

The study was conducted by members of the SLICC network [17]. Data were collected per protocol at enrolment
and annually (±6 months) thereafter and entered into a
centralized database. Each of the participating centre’s
institutional research ethics review boards approved the
SLICC inception cohort study, including this present
analysis.

Patients
Patients fulfilled the ACR classification criteria for SLE
[18] and provided written informed consent for the
SLICC inception cohort. Enrolment occurred up to 15
months following diagnosis. Demographic variables
included age, gender, race/ethnicity and education.
Medication history and lupus-related variables, such as
the SLEDAI-2K [19] and SLICC/ACR damage index (SDI),
were also recorded [20]. Laboratory testing included
haematology, chemistry and immunology required for
SLEDAI-2K and SDI scores. Patient self-reported
HRQoL was measured by the subscale and summary
scores of the Short Form (36 questions) health survey
questionnaire (SF-36) [21].

LN
Nephritis was identified by the renal disorder variable of
the ACR classification criteria [18, 22] and/or biopsy evidence of nephritis as per the International Society of
Nephrology and Renal Pathology Society (ISN/RPS) criteria [23].
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Renal variables and data collection
The SLICC inception cohort was not initially established
for the study of renal disease. Thus, some renal data was
garnered retrospectively by chart review. The ISN/RPS
classification [23] and activity/chronicity scores of Austin
et al. [24] were derived from renal biopsy reports. The
National Kidney Foundation (NKF) classification of chronic
kidney disease (CKD) [25] and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal
Disease equation [26] were determined at each assessment. Estimated proteinuria (ePrU) was measured by
either 24-h urine collection or spot urine total protein:creatinine ratio [27, 28]. ESRD was determined from the SDI
renal variable [29].
At each assessment, patients were assigned to one of
three eGFR and ePrU states. For eGFR: state 1 (eGFR:
>60 ml/min); state 2 (eGFR: 3060 ml/min); and state 3
(eGFR: <30 ml/min). For ePrU: state 1 (ePrU: <0.25 g/day);
state 2 (ePrU: 0.253.0 g/day); and state 3 (ePrU: >3.0 g/
day).

Statistical analyses
Descriptive statistics were used to summarize enrolment
data, and Chi-square tests and t-tests were performed as
appropriate. A simple ordinal regression based on generalized estimating equation (GEE) methods was used to
assess the trends of eGFR and ePrU states as well as
NKF classification of CKD over time after LN diagnosis.
Non-parametric estimates of the cumulative incidence
function for the time until ESRD and death were calculated
using KaplanMeier-like methodology [30]. A Cox regression with a time-varying covariate was also used to examine the effect of LN diagnosis on the competing risks of
ESRD and death. Analyses of HRQoL outcomes at enrolment or at diagnosis of LN were based on simple linear
regression models. For analyses of the HRQoL longitudinal outcomes, linear regression models with GEE were
used to take into account the correlation between multiple
observations within patients. Hypothesis tests for the significance of regression parameters were performed using
Wald tests (Cox regression) and score tests (GEE analyses), and 95% CIs were calculated.

Results
Patients
A total of 1827 patients were recruited between October
1999 and December 2012 from SLICC centres in the USA
[n = 528 (28.9%)], Europe [n = 486 (26.6%)], Canada
[n = 421 (23.0%)], Mexico [n = 223 (12.2%)] and Asia
[n = 169 (9.3%)]. Of these, 89% were female, and at enrolment the mean (S.D.) age of the cohort was 35.1 (13.3)
years with a varied racial/ethnic mix, although predominantly Caucasian (Table 1).
At enrolment, the mean (S.D.) disease duration was 0.5
(0.3) years and patients had low SLEDAI-2K and SDI
scores while receiving a range of lupus medications.
Annual assessments varied from 1 to 13, with a mean
follow-up of 4.6 (3.4) years. Eighty patients (4.4%) were
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lost to follow-up for reasons that included relocation, living
excessive distance from the clinic, referral to a nonparticipating site, voluntary withdrawal and change in insurance status.

Onset and characteristics of patients with LN
LN occurred in 700 (38.3%) patients: 566/700 (80.9%) at
the enrolment visit and 134/700 (19.1%) during follow-up
(Fig. 1). Renal biopsies were performed on 395/700
(56.4%) patients, the majority (86.6%) when nephritis
was first suspected; in 377/395 (95.4%) these were of
sufficient quality to identify ISN/RPS classes (%): I: 9
(2.4), II: 36 (9.5), III: 101 (26.8), IV: 163 (43.2), V: 120
(31.8) and VI: 3 (0.8). Twenty-one and 34 biopsies were
class III/V and IV/V, respectively. Of the 101 class III biopsies, 72 were active (A), 19 were active and chronic (A/C),
and 10 were chronic (C). Among the 163 class IV biopsies,
additional information was available on 127: 50 were class
IV-S (27 A, 16 A/C and 7 C) and 77 were Class IV-G (50 A,
15 A/C and 12 C). For all of the 377 biopsies, the mean
(S.D.) activity index was 4.3 (3.3) and the mean (S.D.) chronicity index was 2.7 (2.6).
There were 547/566 (96.6%) patients with nephritis who
had renal disorder at enrolment. The 19 patients diagnosed only by renal biopsy had the following ISN/RPS
class: I: 4 (21.1), II: 2(10.5), III: 6 (31.6), IV: 5 (26.3), V:
5 (26.3) and VI: 0 (0). There were two and one biopsies
with class III/V and IV/V, respectively. Of the 134 patients
who were diagnosed with LN subsequent to the enrolment
visit, there were 128/134 (94.8%) who had renal disorder.
The six patients diagnosed only by renal biopsy had the
following ISN/RSP classes: I: 1, II: 1, III: 1, IV: 3, V: 0 and
VI: 0.
Patients with LN at enrolment were younger and more
frequently men and of African, Asian and Hispanic race/
ethnicity (Table 1). Nephritis patients had a higher frequency of ACR classification criteria [18] for serositis,
neurological disorder and immunological disorder and a
lower frequency of mucocutaneous disease, arthritis and
ANA. The higher mean total SLEDAI-2K in patients with
nephritis was due to the inclusion of renal variables in the
index score. Both the mean total and similarly adjusted
SDI score was higher in patients with LN. Corticosteroids
and immunosuppressive drugs were used more frequently
and antimalarials less frequently (49.1%) in the nephritis
group at enrolment, although antimalarial use increased to
72% over the study. Hypertension was more frequent in
patients with nephritis.
Of the 1827 patients at the enrolment visit, 96 (5.3%)
were ANA negative. There were no statistically significant
differences in ACR classification criteria between ANApositive and ANA-negative nephritis patients, with the exception of a higher frequency of immunological disorder in
the ANA-positive group (88.4% vs 47.5%, P < 0.001).
Twenty-seven (8/40 ANA-negative nephritis group and
19/56 in non-nephritis group) of the 96 patients who
were ANA negative at enrolment became ANA positive
during the study.
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TABLE 1 Demographic and clinical manifestations of SLE patients with and without LN at enrolment

No. of patients
Age, mean (S.D.), years
Gender, n (%)
Female
Male
Race/ethnicity, n (%)
Caucasian
Hispanic
Asian
African
Other
Disease duration, mean (S.D.), years
ACR classification criteria, n (%)
Malar rash
Discoid rash
Photosensitivity
Oral/nasopharyngeal ulcers
Serositis
Arthritis
Renal disorder
Neurological disorder
Haematologic disorder
Immunologic disorder
ANA
SLEDAI, mean (S.D.)
SLEDAI without renal, mean
SDI score, mean (S.D.)
SDI score without renal, mean (S.D.)
Medications, n (%)
Corticosteroids
Antimalarials
Immunosuppressants
Co-morbidities/lifestyle
Diabetes, n (%)
Hypertension, n (%)
Current smoker, n (%)
Alcohol, mean (S.D.)
BMI, mean (S.D.)
Duration of follow-up
Years, mean (S.D.)

LN patients

Non-LN patients

P-value

All patients

566
31.3 (11.9)

1261
36.9 (13.6)

<0.001

1827
35.1 (13.3)

477 (84.3)
89 (15.7)

1149 (91.1)
112 (8.9)

<0.001

1626 (89.0)
201 (11.0)

182 (32.2)
138 (24.4)
100 (17.7)
121 (21.4)
24 (4.2)
0.5 (0.3)

716 (56.9)
142 (11.3)
172 (13.7)
182 (14.5)
47 (3.7)
0.5 (0.4)

<0.001

898 (49.2)
280 (15.4)
272 (14.9)
303 (16.6)
71 (3.9)
0.5 (0.3)

202 (35.7)
48 (8.5)
140 (24.7)
178 (31.5)
179 (31.6)
380 (67.1)
547 (96.6)
39 (6.9)
366 (64.7)
484 (85.5)
526 (92.9)
8.5 (6.7)
3.6 (3.8)
0.5 (0.9)
0.4 (0.7)

463 (36.7)
179 (14.2)
514 (40.8)
500 (39.7)
318 (25.2)
989 (78.4)
0 (0)
49 (3.9)
760 (60.3)
912 (72.3)
1205 (95.6)
4.0 (4.0)
3.8 (3.7)
0.2 (0.6)
0.2 (0.6)

0.712
<0.001
<0.001
<0.001
0.005
<0.001
0.008
0.083
<0.001
0.027
<0.001
0.393
<0.001
0.008

665 (36.4)
227 (12.4)
654 (35.8)
678 (37.1)
497 (27.2)
1369 (74.9)
547 (29.9)
88 (4.8)
1126 (61.6)
1396 (76.4)
1731 (94.7)
5.4 (5.4)
3.7 (3.7)
0.3 (0.7)
0.3 (0.7)

515 (91.6)
277 (49.1)
397 (70.5)

750 (60.3)
954 (76.0)
331 (26.4)

<0.001
<0.001
<0.001

1265 (70.0)
1231 (67.6)
728 (40.0)

27 (4.8)
330 (58.3)
63 (11.2)
0.6 (1.9)
25.0 (5.9)

37 (3.0)
205 (16.3)
210 (16.7)
1.2 (3.4)
25.4 (5.9)

0.070
<0.001
0.003
<0.001
0.129

64 (3.5)
535 (29.3)
273 (15.0)
1.0 (3.0)
25.3 (5.9)

5.0 (3.6)

4.5 (3.3)

0.008

4.6 (3.4)

Outcome of LN
Adjusting for gender, age at enrolment and race/ethnicity,
a Cox regression analysis on the competing risks of ESRD
and death, with the diagnosis of LN used to define a timedependent covariate, indicated that once patients were
diagnosed with LN, they had higher risks of developing
ESRD [hazard ratio (HR) = 44.7, 95% CI: 6.1, 329.7;
P < 0.001] and death (HR = 3.2, 95% CI: 1.6, 6.5;
P = 0.002).
The estimated cumulative incidence of ESRD (as
defined by the SDI) for the entire cohort at 10 years
following enrolment was 4.3% (95% CI: 2.8%, 5.8%)
(Fig. 2a). For all patients with LN, the cumulative incidence
of ESRD at 10 years after the diagnosis of LN was 10.1%
(95% CI: 6.6%, 13.6%) (Fig. 2b). Excluding patients who
ever developed LN, the estimated cumulative incidence of
ESRD was 0.5% (95% CI: 0%, 1.4%) (Fig. 2c), albeit that

www.rheumatology.oxfordjournals.org

0.353

this is an ad hoc analysis because some patients are
excluded on the basis of developing LN following the
enrolment visit.
The estimated cumulative incidence of death from all
causes for the entire cohort at 10 years after enrolment
was 4.4% (95% CI: 2.7%, 6.1%) (Fig. 2a). Patients with LN
at enrolment and those who never developed LN had a
cumulative incidence of death at 10 years of 5.0% (95%
CI: 2.3%, 7.6%) (Fig. 2d) and 3.6% (95% CI: 0.9%, 6.2%)
(Fig. 2d), respectively. In light of the very significant association between time-dependent LN status and death in
the Cox regression, these overlapping confidence intervals are likely due to the limited data available to estimate
cumulative incidences at single time points late in the
follow-up period. An overall test of a difference in these
curves using the log-rank test of no difference is significant (P = 0.03). The number of patients at the time points
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FIG. 1 Onset of lupus nephritis following enrolment into the SLICC cohort
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FIG. 2 Estimated cumulative incidence of end-stage renal disease and death

End-stage renal disease (all causes) in the total SLICC cohort (A) and in those with (B) and without (C) LN. The estimated
cumulative incidence of death (all causes) for those with LN at enrolment and those who never developed nephritis (D).
ESRD: end stage renal disease.
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TABLE 2 The number (%) of patients in eGFR and ePrU states 13 and in 06 stages of chronic kidney disease at
diagnosis of LN, 3 and 5 years later

eGFR, n (%)
State 1 (eGFR: >60 ml/min)
State 2 (eGFR: 3060 ml/min
State 3 (eGFR: <30 ml/min)
Total
ePrU, n (%)
State 1 (ePrU: <0.25 g/day)
State 2 (ePrU: 0.253.0 g/day)
State 3 (ePrU: >3.0 g/day)
Total
NKF classification of CKD, n (%)
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Total

Diagnosis

3 years after diagnosis

5 years after diagnosis

583 (86.6)
70 (10.4)
20 (3.0)
673

350 (85.2)
44 (10.7)
17 (4.1)
411

248 (87.6)
20 (7.1)
15 (5.3)
283

252 (39.5)
286 (44.8)
100 (15.7)
638

252 (62.2)
134 (33.1)
19 (4.7)
405

173 (62.2)
93 (33.5)
12 (4.3)
278

451
99
60
29
4
9
652

301
36
34
20
4
9
404

196
33
26
12
1
9
277

P-value
0.443

<0.001

0.147
(69.2)
(15.2)
(9.2)
(4.5)
(0.6)
(1.4)

(74.5)
(8.9)
(8.4)
(5.0)
(1.0)
(2.2)

(70.8)
(11.9)
(9.4)
(4.3)
(0.4)
(3.3)

Stage 0: no CKD; Stage 1: kidney damage with normal or increased eGFR (590 ml/min/1.73 m2); Stage 2: kidney damage with
mild decrease in eGFR (6089 ml/min/1.73 m2); Stage 3: moderate decrease in eGFR (3059 ml/min/1.73 m2); Stage 4: severe
decrease in eGFR (1529 ml/min/1.73 m2); Stage 5: kidney failure (<15 ml/min/1.73 m2 or dialysis). The discrepancy between
the number of patients in eGFR states and CKD classification stages is due to methodological differences for making these
determinations: eGFR is measured at a specific time point, whereas CKD classification reflects a persistent abnormality in
eGFR for 53 months and sometimes requires a determination of proteinuria or renal imaging. eGFR: estimated glomerular
filtration rate; ePrU: estimated proteinuria; NKF: National Kidney Foundation; CKD: chronic kidney disease.

for curves in Fig. 2 are provided in a supplementary Table
S1, available at Rheumatology Online. For patients with
LN, the cumulative incidence of death at 10 years following the diagnosis of LN was 5.9% (95%CI: 3.3%, 8.4%)
(Fig. 2b). Of the 39 patients who died, only 1 was due to
ESRD. The others were attributed primarily to cardiorespiratory causes (18), infection (8), neurological disease
(6), malignancy (2) and miscellaneous causes (4).
Additional analyses were performed in which the use of
antimalarials at enrolment was added to the Cox regression analyses [details are provided in a supplementary
Table S2, available at Rheumatology Online]. Controlling
for gender, age at enrolment, race/ethnicity and the diagnosis of LN, antimalarial use at enrolment was not associated with the risk of ESRD (HR = 0.888, 95% CI: 0.473,
1.667; P = 0.711), but patients taking antimalarials at
enrolment had longer survival [HR (for death) = 0.34,
95% CI: 0.15, 0.63; P = 0.001]. Controlling for gender,
age at enrolment, antimalarial use at enrolment and at
the diagnosis of LN, Hispanic patients had shorter survival
than other races/ethnicities [HR (for death) = 2.60 (vs
Caucasian), 95% CI: 1.12, 6.03]. We also examined the
effect of ISN/RPS class on ESRD (n = 16) and death (n = 8).
The global tests on the impact of all ISN/RPS classes on
development of ESRD (P = 0.35) and survival (P = 0.37)
were not statistically significant. However, univariate
analyses revealed a statistically significant association
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between ISN/RPS Class IV LN (vs other ISN/RPS classes)
and the development of ESRD (HR = 2.99, 95% CI: 1.04,
8.62; P = 0.04).
The number and proportion of patients in each of the
three eGFR and ePrU states and CKD stage at LN diagnosis and at the third and fifth annual follow-up assessment after LN diagnosis is summarized in Table 2. There
was no demonstrable change in the distribution of eGFR
states, but there was a markedly lower frequency of ePrU
state 3 over time (P < 0.001). There was no significant
overall change in the proportion of patients with the six
stages of CKD.

LN and HRQoL at enrolment and follow-up
SF-36 subscale and summary scores were not significantly lower in patients with LN at enrolment compared
with the enrolment values for patients who never developed nephritis. However, the subscale scores for
Bodily pain and Vitality scores were lower in non-LN patients (data not shown). Patients with LN and eGFR state 3
at diagnosis had significantly lower scores in three subscales (Physical function, Role physical and Bodily pain)
(Fig. 3) and in the Physical component summary score of
the SF-36 (P < 0.01). These findings were similar when
adjustment was made for age at SLE diagnosis, gender,
location, race/ethnicity, SLEDAI (without renal variables)
and medication. No adjustment could be made for SDI
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FIG. 3 Spidergram of SF-36 subscale scores at diagnosis of lupus nephritis in three eGFR states
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scores due to the short disease duration at enrollment,
which precluded determining an SDI score in many patients. For ePrU states at the same assessments, the Role
physical scores were lower in ePrU state 3 [28.6 (40.5)]
compared with ePrU state 1 [46.8 (42.7)] and state 2 [42.0
(42.8)] (unadjusted global P = 0.008 and P = 0.08 when adjusted for potential confounders).
Adjusting for years after LN diagnosis, there were statistically significant but relatively small declines in SF-36
physical component summary and mental component
summary values for patients in eGFR or ePrU states 2
and 3 over time (Table 3). After adjustment for gender,
age at SLE diagnosis, race/ethnicity, SLEDAI (without
renal variables), medication and SLICC damage score
(without renal variables), all but the relationship between
physical component summary and ePrU states remained
significant (Table 3). There was no statistical evidence for
the dependence of these relationships on time.

Discussion
Since Merrell and Shulman [31] reported a 50% 4-year
survival in the 1950s, renal and overall survival in patients
with LN have steadily improved [32, 33]. This is attributed
to multiple factors, including earlier diagnosis and access
to health care, advances in therapy with immunosuppression, dialysis and transplantation and treatment of comorbidities. However, other studies have suggested that
ESRD and associated mortality have not changed over the
past two decades [3, 4]. The current prospective, observational study reflects the outcome of LN in a large
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international multi-racial/ethnic disease inception cohort
of SLE patients receiving standard of care for up to 12
years. Although the outcomes are generally favourable,
the findings indicate room for further improvement.
The SLICC inception cohort, the largest of its kind, is
well placed to address the objectives of the current study.
The frequency of the initial manifestations of SLE, as reflected by individual ACR classification criteria [18], is
comparable with that of another large cohort [34] and indicates a general lupus population without major selection
bias. At presentation, patients had moderate global SLE
disease activity and mild organ damage. The cumulative
frequency of nephritis of 38.3% in our cohort is very similar to the overall incidence of 37.8% in 2290 SLE patients
enrolled in studies from North America, Europe and the
Middle East [1]. The predilection for nephritis to present
around the time of diagnosis of SLE has also been noted
in another previous large observation study [35]. Other
features such as a higher frequency of nephritis at a
younger age [36, 37], in men [35, 38] and in patients of
non-Caucasian race/ethnicity [3537, 39], and a higher frequency of co-morbidities such as hypertension [40, 41]
provide further evidence for the validity of the cohort
and generalizability of the findings. More frequent use of
corticosteroids and immunosuppressive agents with
nephritis is to be expected and is in line with current treatment guidelines [15, 16].
The outcome of LN has frequently been determined by
total and renal survival, changes in renal function and
achievement of partial or complete remission, albeit variably defined. In the current study, we also selected the
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TABLE 3 Univariate and multivariate regression analysis for SF-36 summary scores over time following the diagnosis
of LN

Parameter
Univariate regression for eGFR states
Intercept
eGFR state 3
eGFR state 2
eGFR state 1
Univariate regression for ePrU states
Intercept
ePrU state 3
ePrU state 2
ePrU state 1
Multiple regression for eGFR and ePrU states
Intercept
Gender
Age at Dx for SLE
Race/ethnicity
Other
African
Asian
Hispanic
Caucasian
SLEDAI w/o renal
SDI w/o renal
54
3
2
1
0
Antimalarials
Immunosuppressants
Corticosteroids
Years since LN
eGFR state 3
eGFR state 2
eGFR state 1
ePrU state 3
ePrU state 2
ePrU state 1

MCS
Estimate (95% CI)

47.84 (47.06 to 48.62)
0.91 ( 3.76 to 1.93)
2.53 ( 4.17 to 0.89)
0
48.21 (47.37 to 49.05)
2.56 ( 4.25 to 0.86)
1.10 ( 1.99 to 0.22)
0
47.70 (44.68 to 50.73)
2.47 (0.46 to 4.47)
0.01 ( 0.07 to 0.05)
0.94
0.41
2.76
3.42
0
0.19

( 2.67 to 4.55)
( 1.88 to 2.70)
(0.55 to 4.96)
(1.27 to 5.57)

0.78
0.32
0.66
0.24
0
0.82
0.19
0.72
0.30
1.74
2.88
0
2.65
0.56
0

(
(
(
(

( 0.36 to
4.62
2.91
1.10
1.33

to
to
to
to

0.02)

P-value

0.019

0.004

0.020
0.724
0.011

0.036
0.911

3.07)
2.28)
2.43)
1.82)

( 1.97 to 0.33)
( 1.37 to 0.99)
( 1.97 to 0.54)
(0.09 to 0.51)
( 4.75 to 1.27)
( 4.55 to 1.21)

0.165
0.750
0.266
0.006
0.008

( 4.54 to 0.76)
( 1.50 to 0.38)

0.020

PCS
Estimate (95% CI)

43.24 (42.47 to 44.01)
4.19 ( 7.09 to 1.28)
1.58 ( 2.99 to 0.16)
0
43.51 (42.63 to 44.38)
3.12 ( 4.69 to 1.56)
0.90 ( 1.74 to 0.06)
0
49.21 (46.01 to 52.40)
2.78 (0.75 to 4.81)
0.17 ( 0.24 to 0.10)
0.04
1.48
3.53
4.95
0
0.34

P-value

0.010

0.004

0.010
<.001
<.001

( 3.87 to 3.95)
( 3.79 to 0.82)
(1.43 to 5.63)
(2.92 to 6.98)
( 0.51 to

0.17)

4.90 ( 7.84 to 1.96)
3.97 ( 6.47 to 1.47)
3.00 ( 4.60 to 1.41)
1.59 ( 3.08 to 0.10)
0
0.20 ( 0.82 to 1.22)
0.19 ( 0.81 to 1.19)
1.97 ( 3.18 to 0.75)
0.33 (0.14 to 0.51)
3.70 ( 6.58 to 0.83)
0.71 ( 2.31 to 0.89)
0
1.33 ( 3.02 to 0.36)
0.21 ( 1.01 to 0.60)
0

<.001
<.001

0.703
0.713
0.002
<.001
0.060

0.302

MCS: mental component summary score of SF-36; PCS: physical component summary score of SF-36; eGFR: estimated
glomerular filtration rate; ePrU: estimated proteinuria; Dx: diagnosis; w/o: without.

hard end-points of total and renal survival, the more frequent and more sensitive outcome of clinically meaningful
defined states for renal function and ePrU, and the association with the less tangible but quantifiable outcome of
HRQoL.
In a European multicentre study of 1000 prevalent SLE
patients [34], 97.1% of whom were white and followed
between 1990 and 2000, the overall 10-year survival
was 92%. In the 279 (27.9%) patients who presented
with nephritis at onset of the study, the 10-year survival
was 88%, compared with 94% in patients without nephropathy. In the current study the estimated 10-year survival
in the entire cohort and in patients with and without nephritis was 95.7, 94.5 and 96%, respectively. Although this
may represent improvement in the outcome of LN, a more
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likely explanation is the inherent difference between a
prevalent and an inception cohort. For example, the
mean disease duration at enrolment into the European
[42] and SLICC cohorts was 6 years and 6 months, respectively, and longer disease duration is an independent
risk for mortality. In both studies, death was attributed to
multiple causes and followed ESRD in only 1/40 (2.5%)
patients in our study.
The frequency of ESRD, as defined by haemodialysis or
renal transplantation, in the European multicentre study
[34] between 1990 and 2000 was 37/1000 (3.7%). Two
recent registry and population health studies in the USA
[36, 37], involving 1156 and 2278 prevalent SLE patients
over 3 years (200204), reported an overall frequency of
ESRD of 6.713.3%, depending upon the case definition
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for ESRD. In both studies, there was a strikingly higher
frequency of LN and ESRD in African Americans, who
were also the major racial/ethnic group. In the current
study, the cumulative incidence of ESRD (as defined by
stage 5 of the NKF classification of CKD) at 5 years was
3.3% and at 10 years following enrolment was 4.3% (as
defined in the SDI). Despite methodological differences in
study design, it is clear that ESRD and increased mortality
persist with current treatment modalities for LN.
The changes in the transition of ePrU states over 3 and
5 years indicate responsiveness to therapy for ePrU over
this time frame. Renal function, reflected by different
eGFR states and the CKD classification, did not change
appreciably. Small changes over time in the eGFR state
distribution cannot be excluded, due to the limited duration of follow-up, but these findings do suggest that
some patients with LN do not respond, in terms of a
marked improvement in renal function, to current treatment modalities, either due to inefficacy, non-adherence
or toxicity necessitating discontinuation of medication.
Relatively few studies have examined HRQoL as a primary outcome in patients with LN. Three studies [4345]
have found that those undergoing treatment for severe LN
have clinically relevant changes in HRQoL up to 1 year
after the commencement of treatment, as quantified by
SF-36 scores. In the current study, HRQoL summary
scores were not lower for patients with nephritis at enrolment when compared with patients who never developed
nephritis. However, patients with the most severe nephritis, as indicated by higher eGFR and ePrU states, had
lower SF-36 subscale and summary scores. This association with lower HRQoL was found in both cross-sectional
and longitudinal analyses, even after adjusting for multiple
potential confounders. Thus, stratification of patients by
severity of LN reveals significant associations with
HRQoL.
There are a number of limitations to the current study.
First treatment decisions were made on the basis of the
physician’s recommendation and patient preference
rather than study protocol. However, this reflects what
occurs in clinical practice and is a strength of the study.
Second, the SLICC network is based within academic
medical centres with a special interest in lupus, and our
data may not fully reflect community clinical practice.
Third, the frequency of renal biopsy was lower than expected. Recent guidelines [15, 16] encourage performing
renal biopsy in all SLE patients with possible renal disease. This permits confirmation of the diagnosis, characterization of glomerular disease and a determination of
overall disease activity and renal scaring, all of which
inform treatment. Despite these advantages, previous observational cohort studies have indicated a highly variable
biopsy rate in 36.8% of 266 [46], 55% of 438 [47], 77% of
26 [48] and 96% of 127 [49] patients with a clinical diagnosis of LN. The reasons for not doing a renal biopsy on
patients in our cohort were multiple and included medical
contraindication, lack of access due to under-insurance in
a fee-for-service system, patient refusal and a low likelihood of influencing the treatment plan, due to other major
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organ involvement. Finally, our study was based upon a
disease inception cohort, and thus the disease duration
was shorter and age at enrolment younger than what is
seen in prevalent cohorts of lupus cases. As both factors
are associated with chronic kidney disease, further followup is necessary to determine the long-term outcome of LN
in this cohort.
Despite these limitations, the study provides useful information on the frequency, characteristics and expectations for outcome in patients with LN receiving current
standard of care. Most of the findings are applicable to
SLE patients in general and set the benchmark for planning future clinical trials of novel therapeutic agents and
protocols.
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